



evidenceFinder



## **Bibliography of all studies in evidenceFinder**

Last updated October 18, 2018



## Ozempic® Phase 3 Studies

1. Ahmann AJ, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. [Link to Access the Full Text](#)
2. Ahren B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. *Lancet Diabetes Endocrinol.* 2017 [Link to Access the Full Text](#)
3. Aroda V, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. *Lancet Diabetes Endocrinol.* 2017 [Link to Access the Full Text](#)
4. Marso S, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *New Engl J Med.* 2016;375(19):1834-1844. [Link to Access the Full Text](#)
5. Pratley R, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol.* 2018 [Link to Access the Full Text](#)
6. Rodbard HW, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomised, controlled trial. *The Journal of Clinical Endocrinology & Metabolism.* 2018;jc.2018-00070-jc.2018-00070. [Link to Access the Full Text](#)
7. Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. 2017;5(4):251-260. [Link to Access the Full Text](#)

## Health Economics and Outcomes Research for Ozempic®

1. Sharma R, et al. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. *Curr Med Res Opin.* 2018:1-9. [Link to Access the Full Text](#)
2. Wilkinson L, et al. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. *Diabetes Therapy.* 2018 [Link to Access the Full Text](#)
3. Witkowski M, et al. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. *Diabetes Ther.* 2018;9(3):1233-1251. [Link to Access the Full Text](#)



## Victoza® Phase 3 Studies

1. Bailey TS, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. *Diabetes, Obesity and Metabolism*. 2016;18(12):1191-1198. [Link to Access the Full Text](#)
2. Buse JB, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009;374(9683):39-47. [Link to Access the Full Text](#)
3. Davies MJ, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. *Diabetes Care*. 2016;39(2):222-30. [Link to Access the Full Text](#)
4. DeVries JH, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. *Diabetes Care*. 2012;35(7):1446-1454. [Link to Access the Full Text](#)
5. Garber A, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet*. 2009;373(9662):473-81. [Link to Access the Full Text](#)
6. Marre M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med*. 2009;26(3):268-78. [Link to Access the Full Text](#)
7. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*. 2016;375(4):311-322. [Link to Access the Full Text](#)
8. Nauck MA, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). *Diabetes Care*. 2009;32:84-90. [Link to Access the Full Text](#)
9. Pratley RE, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. 2010;375(9724):1447-1456. [Link to Access the Full Text](#)
10. Russell-Jones D, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia*. 2009;52(10):2046-2055. [Link to Access the Full Text](#)
11. Zinman B, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). *Diabetes Care*. 2009;32(7):1224-1230. [Link to Access the Full Text](#)



## Health Economics and Outcomes Research for Victoza®

1. Buysman EK, et al. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. *Adv Ther.* 2015;32(4):341-55. [Link to Access the Full Text](#)
2. Chitnis A, et al. Real-World Clinical Effectiveness of Liraglutide in Individuals 65 Years and Older with Type 2 Diabetes in the United. *J Diabetes Metab* 5:403. [Link To Access the Full Text](#)
3. Chitnis AS, et al. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. *Adv Ther.* 2014;31(9):986-99. [Link to Access the Full Text](#)
4. DeKoven M, et al. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. *Adv Ther.* 2014;31(2):202-16. [Link to Access the Full Text](#)
5. Durden E, et al. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States. *J Med Econ.* 2016;19(4):403-13. [Link to Access the Full Text](#)
6. Hunt B, et al. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. *J Med Econ.* 2017:1-4. [Link to Access the Full Text](#)
7. Langer J, et al. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. *J Manag Care Pharm.* 2013;19(3):237-46. [Link to Access the Full Text](#)
8. Lee WC, et al. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. *Curr Med Res Opin.* 2011;27(5):897-906. [Link to Access the Full Text](#)
9. Lee WC, et al. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. *Diabetes Obes Metab.* 2014;16(9):819-26. [Link to Access the Full Text](#)
10. Lee WC, et al. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. *J Med Econ.* 2012;15 Suppl 2:28-37. [Link to Access the Full Text](#)
11. Lee WC, et al. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. *Clin Ther.* 2010;32(10):1756-67. [Link to Access the Full Text](#)
12. Li Q, et al. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. *Diabetes Ther.* 2014;5(2):579-90. [Link to Access the Full Text](#)
13. Li Q, et al. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years. *Diabetes Ther.* 2018;9(3):1279-1293. [Link to Access the Full Text](#)
14. Lorenzi M, et al. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis. *Diabetes Ther.* 2017;8(1):85-99. [Link to Access the Full Text](#)
15. Malmenäs M, et al. Retrospective real-world adherence in patients with type 2 diabetes Initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 µg. *Clin Ther* 2013 Jun; 35(6): 795-807. [Link to Access the Full Text](#)
16. Sullivan SD, et al. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. *Pharmacotherapy.* 2009;29(11):1280-8.
17. Sullivan SD, et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. *Cardiovasc Diabetol.* 2009;8:12. [Link to Access the Full Text](#)



## Xultophy® 100/3.6 mg Phase 3 Studies

1. Billings LK, et al. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial. *Diabetes Care*. 2018;41(5):1009-1016. [Link to Access the Full Text](#)
2. Buse JB, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (Xultophy® 100/3.6). *Diabetes Care*. 2014;37(11):2926-33. [Link to Access the Full Text](#)
3. Lingvay I, et al. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. *JAMA*. 2016;315(9):898-907. [Link to Access the Full Text](#)
4. Linjawi S, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. *Diabetes Ther*. 2017;8(1):101-114. [Link to Access the Full Text](#)

## Health Economics and Outcomes Research for Xultophy® 100/3.6

1. Dempsey M, et al. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. *Journal of Medical Economics*. 2018:1-18. [Link to Access the Full Text](#)
2. Hunt B, et al. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. *J Med Econ*. 2017;20(7):663-670. [Link to Access the Full Text](#)
3. Hunt B, et al. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. *Adv Ther*. 2017;34(4):954-965. [Link to Access the Full Text](#)
4. Hunt B, et al. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. *Diabetes Ther*. 2017;8(3):531-544. [Link to Access the Full Text](#)
5. Dempsey M, et al. Ideglira is Associated with Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S. *Endocr Pract*. 2018;24(9):796-804. [Link to Access the Full Text](#)



## Tresiba® Phase 3 Studies

1. Aroda VR, et al. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). *Diabetes Obes Metab.* 2016;18(7):663-70. [Link to Access the Full Text](#)
2. Bode BW, et al. Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). *Endocr Pract.* 2014;20(8):785-91. [Link to Access the Full Text](#)
3. Bode BW, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN((R)) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. *Diabet Med.* 2013;30(11):1293-7. [Link to Access the Full Text](#)
4. Davies M, et al. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial. *Diabetes Obes Metab.* 2016;18(1):96-9. [Link to Access the Full Text](#)
5. Davies MJ, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. *Diabetes Obes Metab.* 2014;16(10):922-30. [Link to Access the Full Text](#)
6. Garber AJ, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet.* 2012;379(9825):1498-507. [Link to Access the Full Text](#)
7. Gough SC, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. *Diabetes Care.* 2013;36(9):2536-42. [Link to Access the Full Text](#)
8. Heise T, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. *Diabetes Obes Metab.* 2012;14(9):859-64. [Link to Access the Full Text](#)
9. Heller S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet.* 2012;379(9825):1489-97. [Link to Access the Full Text](#)
10. Hollander P, et al. Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. *Diabetes Obes Metab.* 2015;17(2):202-6. [Link to Access the Full Text](#)
11. Lane W, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. *Jama.* 2017;318(1):33-44. [Link to Access the Full Text](#)
12. Marso SP, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med.* 2017;377(8):723-732. [Link to Access the Full Text](#)
13. Mathieu C, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). *Diabetes Obes Metab.* 2014;16(7):636-44. [Link to Access the Full Text](#)
14. Mathieu C, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. *J Clin Endocrinol Metab.* 2013;98(3):1154-62. [Link to Access the Full Text](#)
15. Meneghini L, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. *Diabetes Care.* 2013;36(4):858-64. [Link to Access the Full Text](#)



16. Onishi Y, et al. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. *J Diabetes Investig*. 2013;4(6):605-12. [Link to Access the Full Text](#)
17. Philis-Tsimikas A, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. *Diabetes Obes Metab*. 2013;15(8):760-6. [Link to Access the Full Text](#)
18. Philis-Tsimikas A, et al. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). *Adv Ther*. 2013;30(6):607-22. [Link to Access the Full Text](#)
19. Rodbard HW, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. *Diabet Med*. 2013;30(11):1298-304. [Link to Access the Full Text](#)
20. Thalange N, et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. *Pediatr Diabetes*. 2015;16(3):164-76. [Link to Access the Full Text](#)
21. Warren ML, et al. Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. *Clin Diabetes*. 2017;35(2):90-95. [Link to Access the Full Text](#)
22. Wysham C, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. *Jama*. 2017;318(1):45-56. [Link to Access the Full Text](#)
23. Zinman B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). *Diabetes Care*. 2012;35(12):2464-71. [Link to Access the Full Text](#)

## Health Economics and Outcomes Research for Tresiba®

1. Lane WS, et al. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. *J Med Econ*. 2018;21(2):144-151. [Link to Access the Full Text](#)
2. Weatherall J, et al. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine. *Curr Med Res Opin*. 2017;33(2):231-238. [Link to Access the Full Text](#)
3. Weatherall J, et al. When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation. *Health Qual Life Outcomes*. 2018;16(1):87. [Link to Access the Full Text](#)



### Saxenda® Phase 3 Studies

1. Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial. *Jama-Journal of the American Medical Association*. 2015;314(7):687-699. [Link to Access the Full Text](#)
2. le Roux C, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017 [Link to Access the Full Text](#)
3. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *New England Journal of Medicine*. 2015;373(1):11-22. [Link to Access the Full Text](#)
4. Wadden TA, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. *International Journal of Obesity*. 2013;37(11):1443-1451. [Link to Access the Full Text](#)

### Health Economics and Outcomes Research for Saxenda®

1. Ganguly R, et al. Persistence of newer anti-obesity medications in a real-world setting. *Diabetes Res Clin Pract*. 2018;143:348-356. [Link to Access the Full Text](#)
2. Kolotkin RL, et al. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. *Clin Obes*. 2018;8(1):1-10. [Link to Access the Full Text](#)
3. Kolotkin RL, et al. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. *Clin Obes*. 2016;6(4):233-42. [Link to Access the Full Text](#)